Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.53 |
| ▸ | TUBB | P07437 | 4/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.53 |
| ▸ | KRAS | P01116 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL15135999 | 0.98 | ABCG2 (0.60) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL11157101 | 0.84 | PKM (0.62) | ABCG2ABCB1GAA | |
| SCHEMBL1447168 | 0.84 | DBH (0.55) | ABCG2ABCB1TUBB1TUBB4ATUBB | |
| SCHEMBL6350350 | 0.82 | ABCG2 (0.60) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL10590987 | 0.82 | ABCG2 (0.55) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL11539495 | 0.81 | ABCG2 (0.68) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL8590732 | 0.80 | POLB (0.63) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| Baxitozine SCHEMBL9321098 | 0.79 | ABCG2 (0.66) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL10539610 | 0.79 | ABCG2 (0.57) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL18480640 | 0.79 | ABCG2 (0.66) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116718778-A | Plasma-based markers for evaluating different meal patterns and predictive models | 江苏省人民医院（南京医科大学第一附属医院） | 2023-09-08 | — | — | CN | claimed |
| EP-4548097-A1 | IMMUNOASSAY USING CARBON NANOMATERIALS AND METHOD OF DETECTING TARGET ANTIGEN USING THE SAME | Lee, Ji Hoon (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119497822-A | Immunoassay method based on carbon nanomaterial and method for detecting target antigen by immunoassay method | 李知勋 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024006423-A1 | IMMUNOASSAY USING CARBON NANOMATERIALS AND METHOD OF DETECTING TARGET ANTIGEN USING THE SAME | LEE JI HOON (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240003891-A1 | IMMUNOASSAY USING CARBON NANOMATERIALS AND METHOD OF DETECTING TARGET ANTIGEN USING THE SAME | LEE JI HOON (US) | 2024-01-04 | — | — | US | disclosed |
| CN-116718778-A | Plasma-based markers for evaluating different meal patterns and predictive models | 江苏省人民医院（南京医科大学第一附属医院） | 2023-09-08 | — | — | CN | disclosed |
| CN-116718778-A | Plasma-based markers for evaluating different meal patterns and predictive models | 江苏省人民医院（南京医科大学第一附属医院） | 2023-09-08 | — | — | CN | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021202440-A1 | APTAMERS AGAINST SARS-COV-2, COMPOSITIONS COMPRISING APTAMERS AGAINST SARS-COV-2 AND METHODS OF USING THE SAME | Biovector, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20120021438-A1 | Method of Detecting Target, Method of Suppressing Increase in Background and Detection Apparatus | ARKRAY, INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-2410333-A1 | Method of detecting target, method of suppressing increase in background and detection apparatus | Arkray, Inc. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| EP-0536896-B1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5344925-A | Autoimmune diseases; infections; organ transplants | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5247076-A | IMIDAZOLIDYL MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0536896-A1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1993005059-A1 | IMIDAZOLIDYL MACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | ABCG2 1440/4885TNFRSF1A 1726/4885ABCB1 1983/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | ABCG2 543/4885TNFRSF1A 3242/4885ABCB1 364/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ABCG2 543/4885TNFRSF1A 3242/4885ABCB1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.